Lifeboat Foundation

MEXICO CITY (Reuters) — Mexican authorities said they are studying the case of a 32-year-old female doctor who was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine.

The doctor, whose name has not been released, was admitted to the intensive care unit of a public hospital in the northern state of Nuevo Leon after she experienced seizures, difficulty breathing and a skin rash.

“The initial diagnosis is encephalomyelitis,” the Health Ministry said in a statement released on Friday night. Encephalomyelitis is an inflammation of the brain and spinal cord.

We strongly believe that only digital health can bring healthcare into the 21st century and make patients the point-of-care.

Summary: Treatment with LAU-0901, a synthetic molecule that blocks pro-inflammatory platelet-activating factor, in addition to aspirin-triggered NPD1, reduced the size of damage areas in the brain, initiated repair mechanisms, and improved behavioral recovery following ischemic stroke.

Source: LSU

Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that a combination of an LSU Health-patented drug and selected DHA derivatives is more effective in protecting brain cells and increasing recovery after stroke than a single drug.

Colorado public health officials on Tuesday confirmed the first U.S. case of the new highly contagious strain of the coronavirus that was first discovered in Britain weeks ago, prompting a new set of lockdowns there.

A state lab informed the Centers for Disease Control and Prevention (CDC) about the presence of the strain in a man in his 20s from Elbert County. He has no travel history and is isolating himself until cleared by public health officials, Gov. Jared Polis said in a statement.

STEFANIK CALLS CUOMO ‘ABSOLUTE DISGRACE’ FOR PRIORITIZING DRUG ADDICTS FOR CORONAVIRUS VACCINE

For those of us who don’t think that even our bowel movements will soon be inventoried, tracked and timestamped during every moment of existence, here is a just published white paper from the Rand Corporation, an influential think tank created in 1948 to offer research and analysis to the US military, which begs to differ.

The November 2020 whilte paper, published under the title “The Internet of Bodies,” focuses on the advantages and disadvantages, security and privacy risks, plus the ethical implications of what it calls a growing “Internet of Bodies (IoB).”

IoB tools are internet-connected “smart” devices increasingly available in the marketplace which promise to track and upload to the internet measurements related to individual heartbeat, blood pressure and other bodily functions in real time for purposes of health, exercise, security or other reasons.

In October, threat actors hit the Wyckoff Heights Medical Center in Brooklyn and the University of Vermont Health Network. The cyber attack took place on October 28 and disrupted services at the UVM Medical Center and affiliated facilities.

A month later, the University of Vermont Medical Center was continuing to recover from the cyber attack that paralyzed the systems at the Burlington hospital.

In early December, Hospital CEO Dr. Stephen Leffler announced that the attack that took place in late October on the computer systems of the University of Vermont Medical Center is costing the hospital about $1.5 million a day in lost revenue and recovery costs.

A 75-year-old man from Northern Israel died of a heart attack about two hours after being vaccinated against the novel coronavirus, the Health Ministry has confirmed. The man had pre-existing conditions and had suffered from heart attacks in the past, the ministry said. Health Ministry director-general Chezy Levy has launched an investigation into the incident. “We share in the grief of the family,” Levy said in a statement. The man was inoculated at around 8:30 a.m. at a Clalit clinic. He stayed at the facility, as is customary, for a short period of time to ensure he had no side effects. When he felt well, the clinic released him. Levy noted that the initial findings do not show a link between the man’s death and his vaccination. Recall that when Pfizer presented its safety data to the US Food and Drug Administration back in early December, it was found that two trial participants had died after receiving the vaccine.

A 75-year-old man from Beit She’an died of a heart attack about two hours after being vaccinated against the novel coronavirus on Monday morning, the Health Ministry reported. The man had preexisting conditions and had suffered from heart attacks in the past, it said. Health Ministry director-general Chezy Levy has launched an investigation into the incident. “We share in the grief of the family,” he said in a statement. The man was inoculated at around 8:30 a.m. at a Clalit Health Services clinic. He stayed at the facility, as is customary, for a short period of time to ensure he had no side effects. When he felt well, the clinic released him. The initial findings do not show a link between the man’s death and his vaccination, Levy said. When Pfizer presented its safety data to the US Food and Drug Administration in early December, it was found that two trial participants had died after receiving the vaccine. One of the deceased was immunocompromised, meaning the person’s immune defenses were low. In response to the report of those deaths, Israel’s Midaat Association said when vaccines are administered to at-risk populations, “there may be unfortunate cases. One should not infer from this about the safety of the vaccine, but welcome the transparency required from the pharma companies in the drug approval process.”

The prospect would effectively double the number of vaccine doses available and allow more people to be vaccinated quickly. But the idea has set off a debate, with experts saying there isn’t enough evidence yet to justify a single dose and people should plan to get two doses.

The push in favor of exploring the idea of a single-dose vaccine crystallized with a recent New York Times op-ed from Michael Mina, an immunologist at the Harvard T.H. Chan School of Public Health, and Zeynep Tufecki, a sociologist who has written extensively on the pandemic.

They called for immediately starting a new clinical trial to study whether one dose of the vaccine is sufficient. They cited data from the trials already conducted for the Pfizer and Moderna vaccines that showed protection began after the first dose, with as much as around 90 percent efficacy, compared to around 95 percent efficacy after two doses.

Doses of monoclonal antibodies—Covid-19 therapies authorized for emergency use last month—are sitting unused in hospital pharmacies, even as cases surge across the country.

Hospitals say the rollout of the therapies has been stunted by a lukewarm response from infectious-disease specialists, who say they want more clinical trial data before using them on a regular basis. Medical centers are also grappling with a lack of awareness and interest from both the primary-care doctors who would normally prescribe the drug and patients who are offered it. And some places are dealing with a shortage of space and staff to administer the therapies.

When monoclonal antibody therapies from Eli Lilly & Co. and Regeneron Pharmaceuticals Inc. were approved for emergency use in November, health agencies were worried there wouldn’t be enough supply to meet demand. Now, health-care providers are administering just 20% of the doses they receive each week, according to officials with Operation Warp Speed, the federal initiative to support development of new drugs, vaccines and diagnostics for Covid-19.